NCT06052852View on ClinicalTrials.gov

Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

147

Participants

Timeline

Start Date

October 11, 2023

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2028

Conditions
Triple Negative Breast CancerClear Cell Renal Cell CarcinomaOvarian CancerHead and Neck CancerColorectal CancerNon-small Cell Lung CancerMelanoma
Interventions
DRUG

BDC-3042

Dectin-2 agonist antibody

DRUG

Cemiplimab

Drug which blocks checkpoint proteins from binding with their partner proteins, allowing T cells to kill cancer cells

Trial Locations (6)

22031

NEXT Virginia, Fairfax

77030

MD Anderson Cancer Center, Houston

78229

NEXT Oncology, San Antonio

78758

NEXT Oncology, Austin

94304

Stanford Cancer Center, Palo Alto

02215

Dana-Farber Cancer Institute, Boston

Sponsors
All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Bolt Biotherapeutics, Inc.

INDUSTRY

NCT06052852 - Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies | Biotech Hunter | Biotech Hunter